Search News
| 20.40 Delayed Data As of Apr 20 |  -0.05 / -0.24%Today’s Change | 11.85 Today|||52-Week Range 21.01 | +46.24% Year-to-Date |
| Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug Apr 11 / Zacks.com - Paid Partner Content |
| Previous close | 20.45 |
| Today’s open | 20.35 |
| Day’s range | 20.20 - 20.58 |
| Volume | 290,051 |
| Average volume (3 months) | 849,195 |
| Market cap | $1.4B |
| Earnings growth (last year) | -287.10% |
| Earnings growth (this year) | -0.13% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +26.70% |
| P/E ratio | NM |
| Price/Sales | 7.35 |
| Price/Book | 3.78 |
| Today’s change | Today’s % change | |
|---|---|---|
| SGMOSangamo Therapeutics... | -0.15 | -0.78% |
| XLRNAcceleron Pharma Inc | -0.32 | -0.89% |
| ---- | ||
| EPZMEpizyme Inc | -0.20 | -1.25% |
| Next reporting date | May 1, 2018 |
| EPS forecast (this quarter) | -$0.45 |
| Annual revenue (last year) | $138.9M |
| Annual profit (last year) | -$88.1M |
| Net profit margin | -63.43% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Craig A. Wheeler |
Chief Operating Officer & Chief Scientific Officer Ganesh Venkataraman Kaundinya |
Corporate headquarters Cambridge, Massachusetts |
